April is Parkinson’s Awareness Month, a time to give special attention to a disease that affects approximately 100,000 Canadians. As a centre for both research and clinical treatment of Parkinson’s disease (PD), the Montreal Neurological Institute and Hospital (The Neuro) offers many specialized services and opportunities to participate in research to PD patients.
Industry and academia team up for the benefit of people suffering from ALS
A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.
The partnership between The Montreal Neurological Institute and Hospital (MNI) and Takeda Pharmaceutical Company Limited (Takeda) will allow compounds developed by Takeda scientists to be tested on cell lines produced at the MNI.
Category:
Published on: 4 Dec 2017
